Souheila Abbeddou1, Elizabeth Yakes Jimenez2,3, Sonja Y Hess4, Jérome W Somé5, Jean Bosco Ouédraogo6, Kenneth H Brown4. 1. Public Health Nutrition Unit, Department of Public Health and Primary Care, Ghent University, Campus UZ Gent, Corneel Heymanslaan 10, 9000, Ghent, Belgium. Souheila.Abbeddou@UGent.be. 2. Departments of Pediatrics and Internal Medicine and College of Population Health, University of New Mexico Health Sciences Center, Albuquerque, NM, USA. 3. Research, International and Scientific Affairs, Academy of Nutrition and Dietetics, Chicago, IL, USA. 4. Department of Nutrition and Institute for Global Nutrition, University of California, Davis, CA, USA. 5. Institut de Recherche en Sciences de la Santé, Ouagadougou, Burkina Faso. 6. Institut de Recherche en Sciences de la Santé, Bobo-Dioulasso, Burkina Faso.
Abstract
PURPOSE: Public health interventions to address stunting and wasting should be evaluated for possibly contributing to obesity risk. The present study tested the hypothesis that small-quantity lipid-based nutrient supplements (SQ-LNS) might increase fat deposition, and that additional zinc provided via SQ-LNS or in the form of dispersible tablets would increase fat-free mass (FFM) accretion. METHODS: Using a two-stage, cluster-randomized trial design, 34 communities were randomly assigned to the intervention cohort (IC) or non-intervention cohort (NIC), and family compounds within the IC were randomly assigned to receive different amounts of zinc (0, 5 or 10 mg zinc) incorporated in SQ-LNS or 5 mg zinc in the form of dispersible tablets along with treatment for diarrhea, malaria and fever. Body composition was assessed in a subset of IC (n = 201) and NIC (n = 74) children at 9 and 18 months using the deuterium dilution method. A mixed linear model was used to examine average change in FFM and % fat mass (%FM) among intervention groups and by cohort. RESULTS: Children in the IC had significantly greater change in FFM (Mean (95% Confidence Interval)) (1.57 (1.49, 1.64) kg) compared to the NIC (1.35 (1.23, 1.46) kg; p = 0.005). There were no significant differences in the change in %FM between the NIC and IC or among the intervention groups. CONCLUSION: SQ-LNS, along with morbidity treatment increased weight gain and FFM in young children from 9 to 18 months of age without increasing FM deposition. Additional zinc supplementation did not affect changes in FFM or %FM. TRIAL REGISTRATION: The study was registered as a clinical trial with the US National Institute of Health ( www. CLINICALTRIALS: gov ; NCT00944281).
PURPOSE: Public health interventions to address stunting and wasting should be evaluated for possibly contributing to obesity risk. The present study tested the hypothesis that small-quantity lipid-based nutrient supplements (SQ-LNS) might increase fat deposition, and that additional zinc provided via SQ-LNS or in the form of dispersible tablets would increase fat-free mass (FFM) accretion. METHODS: Using a two-stage, cluster-randomized trial design, 34 communities were randomly assigned to the intervention cohort (IC) or non-intervention cohort (NIC), and family compounds within the IC were randomly assigned to receive different amounts of zinc (0, 5 or 10 mg zinc) incorporated in SQ-LNS or 5 mg zinc in the form of dispersible tablets along with treatment for diarrhea, malaria and fever. Body composition was assessed in a subset of IC (n = 201) and NIC (n = 74) children at 9 and 18 months using the deuterium dilution method. A mixed linear model was used to examine average change in FFM and % fat mass (%FM) among intervention groups and by cohort. RESULTS: Children in the IC had significantly greater change in FFM (Mean (95% Confidence Interval)) (1.57 (1.49, 1.64) kg) compared to the NIC (1.35 (1.23, 1.46) kg; p = 0.005). There were no significant differences in the change in %FM between the NIC and IC or among the intervention groups. CONCLUSION: SQ-LNS, along with morbidity treatment increased weight gain and FFM in young children from 9 to 18 months of age without increasing FM deposition. Additional zinc supplementation did not affect changes in FFM or %FM. TRIAL REGISTRATION: The study was registered as a clinical trial with the US National Institute of Health ( www. CLINICALTRIALS: gov ; NCT00944281).
Authors: Kenneth M Maleta; John Phuka; Lotta Alho; Yin Bun Cheung; Kathryn G Dewey; Ulla Ashorn; Nozgechi Phiri; Thokozani E Phiri; Stephen A Vosti; Mamane Zeilani; Chiza Kumwenda; Jaden Bendabenda; Anna Pulakka; Per Ashorn Journal: J Nutr Date: 2015-06-10 Impact factor: 4.798
Authors: Robert E Black; Cesar G Victora; Susan P Walker; Zulfiqar A Bhutta; Parul Christian; Mercedes de Onis; Majid Ezzati; Sally Grantham-McGregor; Joanne Katz; Reynaldo Martorell; Ricardo Uauy Journal: Lancet Date: 2013-06-06 Impact factor: 79.321
Authors: Linda S Adair; Caroline H D Fall; Clive Osmond; Aryeh D Stein; Reynaldo Martorell; Manuel Ramirez-Zea; Harshpal Singh Sachdev; Darren L Dahly; Isabelita Bas; Shane A Norris; Lisa Micklesfield; Pedro Hallal; Cesar G Victora Journal: Lancet Date: 2013-03-28 Impact factor: 79.321
Authors: Sonja Y Hess; Souheila Abbeddou; Elizabeth Yakes Jimenez; Jérôme W Somé; Stephen A Vosti; Zinéwendé P Ouédraogo; Rosemonde M Guissou; Jean-Bosco Ouédraogo; Kenneth H Brown Journal: PLoS One Date: 2015-03-27 Impact factor: 3.240
Authors: Cesar G Victora; Linda Adair; Caroline Fall; Pedro C Hallal; Reynaldo Martorell; Linda Richter; Harshpal Singh Sachdev Journal: Lancet Date: 2008-01-26 Impact factor: 79.321